Kollitab™ DC 87 L – Your new all-in-one tableting solution, with filler, binder, disintegrant and lubricant
Coprocessed excipients in the pharmaceutical industry are substances created by combining two or more individual excipients through various processing techniques to physically modify their properties without significant chemical change.
At BASF, our coprocessed excipients have been strategically designed to address the entire value chain. Whether you are looking to improve drug processability or expedite product development by having access to formulation predictions and simplifying manufacturing using a direct compression process, coprocessed excipients are developed with success in mind.
BASF carefully developed a formulation combining filler, binder, disintegrant, and lubricant, then spray-dried it to produce the all-in-one Kollitab™ DC 87 L; this generates one consistent material with unique properties when compared to a simple excipients blend. Kollitab™ DC 87 L was designed to provide better flowability, higher compressibility, and faster tablet disintegration than a mix of the same individual materials that make it up, though the chemical properties of the ingredients do not change.
Read more in the text and brochure below:
Kollitab™ DC 87 L
BASF’s premium coprocessed excipient is optimized for your direct compression processes.
Our scientists carefully designed this best-in-class product to maximize flowability and tablet strength, with a formulation that has high stability and low sensitivity to overblending. Its round particle shape ensures excellent flowability from feeder hoppers and during tableting, for high process robustness and low tablet weight variability.
Kollitab™ DC 87 L can produce strong tablets across a broad range of compression forces, reducing both stress and punch damage on the tablet press, for better machine durability and less tablet defects.
This product ensures fast tablet disintegration to quickly deliver the intended benefits of your API. This is especially valuable for high-strength tablets that tend to take longer to disintegrate.
How can Kollitab™ DC 87 L help you?
Superior Flowability
For high process consistency.
High Tablet Strength
At broad compression forces to minimize tablet defects.
Fast Disintegration
For unhindered drug dissolution.
Key benefits
Manufacturing
- Enables fast tablet development
- Simplifies formulation development
- Reduces manufacturing complexity
Quality & Regulatory
- Based on monographed excipients
- Provides advantages of all-in-one products (reduced Quality Control efforts, handling, and documentation)
Kollitab™ DC 87 L Technical Features
“In our daily working life at IMA, tablet presses need to be tested for different purposes, including to demonstrate to customers the perfect performance of the equipment. Thus, it is mandatory for IMA to have an all-in-one blend that is stable and reliable. Since the beginning, the cooperation with BASF fulfilled this need, even though our requirements for powder processability and low dust are quite strict. Under stressful conditions, with different punches and at full nominal speed, the machine always achieved excellent results, with low weight variations, stable thickness, and enhanced tablet strength. Kollitab™ DC 87 L did not require any process optimization to speed up the tablet press. We also tested the machine for hours, always with reliable and good results for the tensile strength and tablet weight. Kollitab™ DC 87 L confirmed and showed how reliable and flexible our machines are, and how easily one can use them without any need for process optimization.”
See the full technical brochure on “Kollitab™ DC 87 L” here
(click the picture to download the brochure)
Source: BASF technical brochure “Kollitab™ DC 87 L”
Read more: BASF website Kollitab™ DC 87 L
Leverage Kollitab™ DC 87 L in ZoomLab® for FREE to accelerate formulation and time-to-market:
ZoomLab® Phase Diagram of Solid Dispersion
